Insulin-like growth factors and liver cancer risk in male smokers
- PMID: 20717109
- PMCID: PMC2965858
- DOI: 10.1038/sj.bjc.6605842
Insulin-like growth factors and liver cancer risk in male smokers
Abstract
Background: The liver is the primary source of circulating insulin-like growth factor (IGF)-I, yet the relation between IGFs and liver cancer is uncertain.
Methods: In a case-cohort study within a cohort of 29,133 male smokers we examined associations of serum IGF-I and IGF binding protein (IGFBP)-3 with liver cancer (50 cases).
Results: Nonlinear associations between liver cancer and IGF-I and IGFBP-3 were observed (P=0.04 and P<0.01, respectively), strongest association at lowest levels (odds ratio (OR)=0.2, 95% confidence interval (CI)=0.1-0.7 for 80 vs 30 ng ml(-1) of IGF-I; OR=0.2, 95% CI=0.1-0.6 for 1400 vs 700 ng ml(-1) of IGFBP-3).
Conclusions: Low IGF-I and IGFBP-3 levels in male smokers are associated with increased risk of liver cancer.
Similar articles
-
Associations of Insulin and IGFBP-3 with Lung Cancer Susceptibility in Current Smokers.J Natl Cancer Inst. 2016 Apr 12;108(7):djw012. doi: 10.1093/jnci/djw012. Print 2016 Jul. J Natl Cancer Inst. 2016. PMID: 27071409 Free PMC article.
-
Insulin-like growth factors and insulin-like growth factor binding proteins in adult patients with severe liver disease before and after orthotopic liver transplantation.Horm Res. 2002;57(3-4):105-12. doi: 10.1159/000057960. Horm Res. 2002. PMID: 12006706
-
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort.Cancer Epidemiol Biomarkers Prev. 2002 Nov;11(11):1413-8. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12433720 Clinical Trial.
-
Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7. doi: 10.1093/jnci/92.23.1910. J Natl Cancer Inst. 2000. PMID: 11106682
-
Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.J Natl Cancer Inst. 1999 Jan 20;91(2):151-6. doi: 10.1093/jnci/91.2.151. J Natl Cancer Inst. 1999. PMID: 9923856
Cited by
-
Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.Oncol Lett. 2012 Mar;3(3):704-712. doi: 10.3892/ol.2011.546. Epub 2011 Dec 30. Oncol Lett. 2012. PMID: 22740980 Free PMC article.
-
Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B.Sci Rep. 2021 Nov 15;11(1):21194. doi: 10.1038/s41598-021-00455-8. Sci Rep. 2021. PMID: 34782638 Free PMC article.
-
Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals.Aliment Pharmacol Ther. 2021 Sep;54(6):833-842. doi: 10.1111/apt.16524. Epub 2021 Jul 19. Aliment Pharmacol Ther. 2021. PMID: 34286851 Free PMC article.
-
Serum insulin-like growth factor-1 and its binding protein 3 as prognostic factors for the incidence, progression, and outcome of hepatocellular carcinoma: a systematic review and meta-analysis.Oncotarget. 2017 Jul 12;8(46):81098-81108. doi: 10.18632/oncotarget.19186. eCollection 2017 Oct 6. Oncotarget. 2017. PMID: 29113370 Free PMC article.
-
Circulating Insulin-Like Growth Factor-1 and Risk of Total and 19 Site-Specific Cancers: Cohort Study Analyses from the UK Biobank.Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2332-2342. doi: 10.1158/1055-9965.EPI-20-0743. Epub 2020 Aug 20. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32856611 Free PMC article.
References
-
- Bosch FX, Ribes J, Diaz M, Cleries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(5 Suppl 1): S5–S16 - PubMed
-
- Buzzelli G, Dattolo P, Pinzani M, Brocchi A, Romano S, Gentilini P (1993) Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol 88(10): 1744–1748 - PubMed
-
- Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279(5350): 563–566 - PubMed
-
- Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94(14): 1099–1106 - PubMed
-
- Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, Barrett JC (1997) Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res 57(21): 4667–4672 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous